StockWorld News

AstraZeneca CEO: ‘each of our businesses grew a lot in Q1’

AstraZeneca CEO: ‘each of our businesses grew a lot in Q1’

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >

By:

Wajeeh Khan

on
Apr 29, 2022

AstraZeneca plc reports a 60% year-over-year growth in its Q1 revenue.

CEO Pascal Soriot discussed results and outlook on CNBC Street Signs Europe.

AstraZeneca shares have gained over 15% since the start of the year 2022.

AstraZeneca plc (LON: AZN) on Friday said vaccine contracts helped its Q1 financial results. Moving forward, however, it expects COVID-related sales to sink by 21% to 25%. The stock is nearly flat today.

Notable figures in AstraZeneca Q1 results

The British-Swedish multinational reported $11.39 billion in first-quarter – a significant increase from last year’s $7.32 billion. Strength of its revenue, AstraZeneca added, was also attributed to $13.3 billion acquisition of Alexion Pharmaceuticals.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Core earnings per share in Q1 jumped 20% to $1.89. On CNBC’s “Street Signs Europe”, CEO Pascal Soriot said:

We had a fantastic quarter with 60% growth in our total revenue. Each of our businesses and every geography grew quite a lot.

AstraZeneca reiterated fiscal 2022 guidance

For fiscal 2022, AstraZeneca forecasts high-teens percentage increase in total revenue. It expects 25% to 29% growth in core EPS this year, as per the earnings press release. Discussing the impact of COVID on other segments of the business, the chief executive noted:

It’s still affecting diagnosis and treatment of patients. There’s also a lot of backlog in many hospitals around the world. But we are starting to see some improvements. So, things are really looking up.

Soriot expects a “return to normal” in the back half of 2022, given no new, substantial peak in COVID. The stock is up more than 15% for the year.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,
eToro

10/10

68% of retail CFD accounts lose money

Visit site

Biotech


Europe


Health & pharmaceuticals


Industries


Stocks & Shares


UK


World